Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A

Handbook of Experimental Pharmacology

Volumn 202, Issue , 2011, Pages 345-374

  Charrua, Ana ^a,b   Avelino, António ^a,b   Cruz, Francisco ^b,c  

^a Institute of Histology and Embryology   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Bladder; BoNT A; Pain; Prostate; TRPV1; TRPV1b

Indexed keywords

ANANDAMIDE; BOTULINUM TOXIN; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; CANNABINOID 1 RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; NERVE GROWTH FACTOR; PLACEBO; PROTEIN KINASE C; RESINIFERATOXIN; SUBSTANCE P; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROTOXIN; TRPV1 PROTEIN, HUMAN; VANILLOID RECEPTOR;

ARTICLE; BLADDER INNERVATION; CELL MEMBRANE; CYSTALGIA; CYSTITIS; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; HYPERTHERMIA; INTERSTITIAL CYSTITIS; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; NEUROGENIC BLADDER; NEUROPATHIC PAIN; NEUROTRANSMITTER RELEASE; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; SINGLE DRUG DOSE; SPINAL GANGLION; URINARY TRACT INFLAMMATION; URINE INCONTINENCE; ANIMAL; BLADDER; DRUG EFFECT; INNERVATION; INTRAVESICAL DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; ANIMALS; BOTULINUM TOXINS, TYPE A; HUMANS; MUSCARINIC ANTAGONISTS; NEUROTOXINS; TREATMENT OUTCOME; TRPV CATION CHANNELS; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 79952207128     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-16499-6_17     Document Type: Article

References (271)

1. Ahern GP, Brooks IM, Miyares RL, Wang XB (2005) Extracellular cations sensitize and gate capsaicin receptor TRPV1 modulating pain signalling. J Neurosci 25: 5109-5116 (Pubitemid 40726964)
2. Amadesi S, Cottrell GS, Divino L, Chapman K, Grady EF, Bautista F, Karanjia R, Barajas-Lopez C, Vanner S, Vergnolle N, Bunnett NW (2006) Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice. J Physiol 575: 555-571 (Pubitemid 44270181)
3. Amaya F, Oh-hashi K, Naruse Y, Iijima N, Ueda M, Shimosato G, Tominaga M, Tanaka Y, Tanaka M (2003) Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons. Brain Res 963: 190-196 (Pubitemid 36126299)
4. Ambache N (1949) The peripheral action of Cl, Botulinum toxin. J Physiol 108: 127-141
5. Aoki KR (2005) Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26: 785-793
6. Apostolidis A, Brady CM, Yiangou Y, Davis J, Fowler CJ, Anand P (2005a) Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin, Urology 65: 400-405 (Pubitemid 40248050)
7. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P (2005b) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174: 977-982 (Pubitemid 41140654)
8. Apostolidis A, Gonzales GE, Fowler CJ (2006a) Effect of intravesical resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Eur Urol 50: 1299-1305 (Pubitemid 44692915)
9. Apostolidis A, Dasgupta P, Fowler CJ (2006b) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49: 644-650 (Pubitemid 43374724)
10. 2+ sensor of fast neurotransmitter release, Cell Mol Neurobiol 21: 717-731
11. Avelino A, Cruz F (2010) TRPV1 in visceral pain and other visceral disorders. In: Gomtsyan A, Faltynek CR (eds) Vanilloid receptor TRPV1 in drug discovery. Wiley Ed, New York, pp 206-238, Chap 8
12. Avelino A, Cruz C, Nagy I, Cruz F (2002) Vanilloid receptor 1 expression in the rat urinary tract, Neuroscience 109: 787-798 (Pubitemid 34260863)
13. Bevan S, Hothi S, Hughes G, James IF, Rang HP, Shah K, Walpole CSJ, Yeats JC (1992) Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br J Pharmacol 107: 544-552
14. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RW 4th (2002) cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 35: 721-731 (Pubitemid 35223031)
15. Binz T, Rummel A (2009) Cell entry strategy of clostridial neurotoxins, J Neurochem 109: 1584-1595
16. Binz T, Bade S, Rummel A, Kollewe A, Alves J (2002) Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization. Biochemistry 41: 1717-1723 (Pubitemid 34132245)
17. Birder LA, Kanai AJ, de Groat WC, Kiss S, Nealen ML, Burke NE et al (2001) Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci 98: 13396-13401 (Pubitemid 33051374)
18. Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, Wang F, Ruiz G, de Groat WC, Apadoca G, Watkins S, Caterina MJ (2002) Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosa 5: 856-860 (Pubitemid 34976650)
19. Birder LA, Wolf-Johnston A, Griffiths D, Resnick NM (2007) Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn 26: 405-409 (Pubitemid 46717590)
20. Blaustein RO, Germann WJ, Finkelstein A, DasGupta BR (1987) The N-terminal half of the heavy chain of botulinum type A neurotoxin forms channels in planar phospholipid bilayers. FEBS Lett 226: 115-120
21. Bodo E, Bíró T, Telek A, Czifra G, Griger Z, Tóth BI, Mescalchin A, Ito T, Bettermann A, Kovács L, Paus R (2005) A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/ TRPV1) signaling in human hair growth control. Am J Pathol 166: 985-998 (Pubitemid 40524424)
22. Bonnington JK, McNaughton PA (2003) Signalling pathways involved in the sensitisation of mouse nociceptive neurons by nerve growth factor. J Physiol 551: 433-446 (Pubitemid 37121702)
23. Brady CM, Apostolidis AN, Harper M, Yiangou Y, Beckett A, Jacques TS, Freeman A, Scaravilli F, Fowler CJ, Anand P (2004a) Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 93: 770-776 (Pubitemid 38497026)
24. Brady CM, Apostolidis A, Yiangou Y, Baecker PA, Ford AP, Freeman A, Jacques TS, Fowler CJ, Anand P (2004b) P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin, Eur Urol 46: 247-253
25. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J, Pelvic Floor Disorders Network (2008) Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180 (1): 217-222
26. Brunger AT, Rummel A (2009) Receptor and substrate interactions of clostridial neurotoxins, Toxicon 54: 550-560
27. Brunger AT, Jin R, Breidenbach MA (2008) Highly specific interactions between botulinum neurotoxins and synaptic vesicle proteins. Cell Mol Life Sci 65: 2296-2306
28. Burgen ASV, Dickens F, Zatman LJ (1949) The action of botulinum toxin on the neuro-muscular junction. J Physiol 109: 10-24
29. Cai S, Kukreja R, Shoesmith S, Chang TW, Singh BR (2006) Botulinum neurotoxin light chain refolds at endosomal pH for its translocation. Protein J 25: 455-462 (Pubitemid 44934689)
30. Carlton SM, Coggeshall RE (2001) Peripheral capsaicin receptors increase in the inflamed rat hindpaw: a possible mechanism for peripheral sensitization. Neurosci Lett 310: 53-56 (Pubitemid 32778483)
31. Carlton SM, Du J, Zhou S (2009) Group II metabotropic glutamate receptor activation on peripheral nociceptors modulates TRPV1 function. Brain Res 1248: 86-95
32. Carr MJ, Lollarik M, Meeker SN, Undem BJ (2003) A role for TRPV1 in bradykinin-induced excitation of vagal airway afferent nerve terminals, J Pharmacol Exp Ther 304: 1275-1279 (Pubitemid 36254441)
33. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389: 816-824 (Pubitemid 27462969)
34. Caterina MJ, Lefber A, Malmberg AB, Martin WJ, Trafton J, Petersen KR, Koltzenburg M, Basbaum AI, Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288: 306-313 (Pubitemid 30226186)
35. Chai TC, Gray ML, Steers W (1998) The incidence of a positive ice water test in bladder outlet obstructed patients: evidence for bladder neural plasticity, J Urol 160: 34-38 (Pubitemid 29479410)
36. Chancellor MB, de Groat WC (1999) Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 162: 3-11 (Pubitemid 29420868)
37. Chandiramani VA, Peterson T, Duthie GS, Fowler CJ (1996) Urodynamic changes during therapeutic intravesical instillations of capsaicin. Br J Urol 77: 792-797 (Pubitemid 27407584)
38. Charrua A, Cruz CD, Cruz F, Avelino A (2007) Transient receptor potential vanilloid subfamily 1 is essential for the generation of noxious bladder input and bladder overactivity in cystitis. J Urol 177: 1537-1541 (Pubitemid 46436017)
39. Charrua A, Reguenga C, Paule CC, Nagy I, Cruz F, Avelino A (2008) Cystitis is associated with TRPV1b-downregulation in rat dorsal root ganglia. NeuroReport 19: 1469-1472
40. Charrua A, Reguenga C, Cordeiro JM, Correiade-Sá P, Paute C, Nagy I, Cruz F, Avelino A (2009a) Functional transient receptor potential vanilloid 1 is expressed in human urothelial cells. J Urol 182: 2944-2950
41. Charrua A, Cruz CD, Narayanan S, Gharat L, Gullapalli S, Cruz F, Avelino A (2009b) GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol 181: 379-386
42. 2+ and drives membrane fusion. Cell 97: 165-174
43. Chen TY, Coreos J, Camel M, Ponsot Y, Tu le M (2005) Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC). Int Urogynecol J Pelvic Floor Dysfunct 16: 293-297 (Pubitemid 41511166)
44. Chu CJ, Huang SM, De Petrocellis L, Bisogno T, Ewing SA, Miller JD, Zipkin RE, Daddario N, Appendino G, Di Marzo V, Walker JM (2003) N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem 278: 13633-13639 (Pubitemid 36799898)
45. Chuang HH, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI, Chao MV, Julius D (2001) Bradykinin and nerve growth factor release the capsaicin receptor from Ptdlns(4, 5) P2mediated inhibition. Nature 411: 957-962
46. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB (2004) Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 172: 1529-1532 (Pubitemid 39249763)
47. Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB (2005) Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66: 775-779 (Pubitemid 41440823)
48. Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, Malmberg AB, Cain G, Benson A, Kassotakis L, Hedley L, Lachnit WG, Burnstock G, McMahon SB, Ford AP (2000) Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407: 1011-1015
49. Coelho A, Dinis P, Pinto R, Gorgal T, Silva C, Silva A, Silva J, Cruz CD, Cruz F, Avelino A (2009) Mechanisms of action of botulinum toxin type A: distribution of its high affinity binding site and intracellular target in the human bladder. Eur Urol 56: 134-140
50. Cruz F, Silva C (2006) Refractory neurogenic detrusor overactivity. Int J Clin Pract 60: 22-26 (Pubitemid 44803946)
51. Cruz F, Guimarães M, Silva C, Rio ME, Coimbra A, Reis M (1997a) Desensitization of bladder sensory fibres by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. J Urol 157: 585-589 (Pubitemid 27026844)
52. Cruz F, Guimaräes M, Silva C, Reis M (1997b) Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 350: 640-641 (Pubitemid 27367806)
53. da Silva CM, Cruz F (2009) Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it? Curr Opin Urol 19: 347-352
54. Das A, Chancellor MB, Watanabe T, Sedor J, Rivas DA (1996) Intravesical capsaicin in neurologic impaired patients with detrusor hyperreflexia. J Spinal Cord Med 19: 190-193 (Pubitemid 126766580)
55. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405: 183-187 (Pubitemid 30313536)
56. de Groat WC (1997) A neurologic basis for the overactive bladder. Urology 50: 36-52
57. de Haro L, Quetglas S, Iborra C, Lévêque C, Seagar M (2003) Calmodulin-dependent regulation of a lipid binding domain in the v-SNARE synaptobrevin and its role in vesicular fusion. Biol Cell 95: 459-464 (Pubitemid 37441637)
58. de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96: 3200-3205 (Pubitemid 29148868)
59. de Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, Baert L, Fowler CJ (1997) Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with longterm followup, J Urol 158: 2087-2092 (Pubitemid 27481333)
60. de Séze M, Wiart L, Joseph PA, Dosque JP, Mazaux JM, Barat M (1998) Capsaicin and neurogenic detrusor hyperreflexia. A double blind placebo controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 17: 513-523
61. de Sèze M, Wiart L, Ferrière J, de Sèze MP, Joseph P, Barat M (1999) Intravesical instillation of capsaicin in urology: a review of the literature. Eur Urol 36: 267-277 (Pubitemid 29419441)
62. de Sèze M, Wiart L, de Sèze MP, Soyeur L, Dosque JP, Blajezewski S, Moore N, Brochet B, Mazaux JM, Barat M, Joseph PA (2004) Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 171: 251-255 (Pubitemid 37549136)
63. de Sèze M, Gallien P, Denys P, Labat JJ, Serment G, Grise P, Salle JY, Blazejewski S, Hazane C, Moore N, Joseph PA (2006) Intravesical glucidic capsaicin versus glucidic solvent in neurogenic detrusor overactivity: a double blind controlled randomized study. Neurourol Urodyn 25: 752-757 (Pubitemid 44691379)
64. Dickenson AH, Dray A (1991) Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception. Br J Pharmacol 104: 1045-1049
65. Dickson EC, Shevky R (1923) Botulism. Studies on the manner in which the toxin of Clostridium botulinum acts upon the body: I. The effect upon the autonomic nervous system, J Exp Med 37: 711-731
66. Dinis P, Charrua A, Avelino A, Yaqoob M, Bevan S, Nagy I, Cruz F (2004a) Anandamideevoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci 24: 11253-11263 (Pubitemid 39658260)
67. Dinis P, Silva J, Ribeiro MJ, Avelino A, Reis M, Cruz F (2004b) Bladder C-fiber desensitization induces a long-lasting improvement of BPH-associated storage LUTS: a pilot study. Eur Urol 46: 88-93
68. Dinis P, Charrua A, Avelino A, Nagy I, Quintas J, Ribau U, Cruz F (2005) The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate. Eur Urol 48: 162-167 (Pubitemid 40835615)
69. Dmitrieva N, McMahon SB (1996) Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 66: 87-97 (Pubitemid 26247028)
70. Docherty RJ, Yeats JC, Bevan S, Boddeke HW (1996) Inhibition of calcineurin inhibits the desensitization of capsaicin-evoked currents in cultured dorsal root ganglion neurones from adult rats. Pflugers Arch 431: 828-837 (Pubitemid 26134693)
71. Docherty RJ, Yeats JC, Piper AS (1997) Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurons in culture. BrJ Pharmacol 121: 1461-1467 (Pubitemid 27317561)
72. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA (1998) Botox-induced prostatic involution, Prostate 37: 44-50 (Pubitemid 28385184)
73. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592-596
74. Duggan MJ, Quinn CP, Chaddock JA, Purkiss JR, Alexander FC, Doward S, Fooks SJ, Friis LM, Hall YH, Kirby ER, Leeds N, Moulsdale HJ, Dickenson A, Green GM, Rahman W, Suzuki R, Shone CC, Foster KA (2002) Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 277: 34846-34852
75. Dunant Y, Esquerda JE, Loctin F, Marsal J, Muller D (1987) Botulinum toxin inhibits quantal acetylcholine release and energy metabolism in the Torpedo electric organ, J Physiol 385: 677-692 (Pubitemid 17048956)
76. Dunant Y, Loctin F, Marsal J, Muller D, Parducz A, Rabasseda X (1988) Energy metabolism and quantal acetylcholine release: effects of botulinum toxin, 1-fluoro-2, 4-dinitrobenzene, and diamide in the Torpedo electric organ. J Neurochem 50 (2): 431-439
77. Dunant Y, Esquerda JE, Loctin F, Marsal J, Muller D (1990) Type A botulinum toxin disorganizes quantal acetylcholine release and inhibits energy metabolism. J Physiol Paris 84 (3): 211-219
78. Edmunds CW, Long PH (1923) Contribution to the pathologic physiology of botulism J. Am Med Ass 81: 542-547
79. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, Lafolie P (2007) Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study, Scand J Urol Nephrol 41 (4): 335-340 (Pubitemid 47357195)
80. Eilers H, Lee SY, Hau CW, Logvinova A, Schumacher MA (2007) The rat vanilloid receptor splice variant VR.5'sv blocks TRPV1 activation. NeuroReport 18: 969-973 (Pubitemid 46905167)
81. Everaerts W, Sepulveda MR, Gevaert T, Roskams T, Nilius B, de Ridder D (2009) Where is TRPV1 expressed in the bladder, do we see the real channel? Naunyn Schmiedebergs Arch Pharmacol 379: 421-425
82. Fagerli J, Fraser MO, deGroat WC, Chancellor MB, Flood HD, Smith D, Jordan ML (1999) Intravesical capsaicin for the treatment of interstitial cystitis: a pilot study. Can J Urol 6: 737-744
83. Ferreira J, da Silva GL, Calixto JB (2004) Contribution of vanilloid receptors to the overt nociception induced by B2 kinin receptor activation in mice. Br J Pharmacol 141: 787-794 (Pubitemid 38446179)
84. Ferrer-Montiel AV, Canaves JM, DasGupta BR, Wilson MC, Montai M (1996) Tyrosine phosphorylation modulates the activity of clostridial neurotoxins. J Biol Chem 271: 18322-18325 (Pubitemid 26322682)
85. Fischer A, Montai M (2007a) Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem 282: 29604-29611 (Pubitemid 350043363)
86. Fischer A, Montai M (2007b) Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci USA 104: 10447-10452
87. Fischer A, Mushrush DJ, Lacy DB, Montal M (2008) Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog 4: e1000245
88. Fowler CJ, Jewkes D, McDonald WI, Lynn B, de Groat WC (1992) Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 339: 1239
89. Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG (1994) Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 57: 169-173 (Pubitemid 24050455)
90. Fujinaga Y, Takeshi K, Inoue K, Fujita R, Ohyama T, Moriishi K, Oguma K (1995) Type A and B neurotoxin genes in a Clostridium botulinum type AB strain. Biochem Biophys Res Commun 213: 737-745
91. Galloux M, Vitrac H, Montagner C, Raffestin S, Popoff MR, Chenal A, Forge V, Gillet D (2008) Membrane interaction of botulinum neurotoxin A translocation (T) domain. The belt region is a regulatory loop for membrane interaction. J Biol Chem 283: 27668-27676
92. Gavva NR, Bannon AW, Surapaneni S, Hovland DN Jr, Lehto SG, Gore A, Juan T, Deng H, Han B, Klionsky L, Kuang R, Le A, Tamir R, Wang J, Youngblood B, Zhu D, Norman MH, Magal E, Treanor JJ, Louis JC (2007) The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation, J Neurosci 27: 3366-3374 (Pubitemid 46515121)
93. Gavva NR, Treanor JJ, Garami A, Fang L, Surapaneni S, Akrami A, Alvarez F, Bak A, Darling M, Gore A, Jang GR, Kesslak JP, Ni L, Norman MH, Palluconi G, Rose MJ, Salfi M, Tan E, Romanovsky AA, Banfield C, Davar G (2008) Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 136: 202-210
94. Geirsson G, Fall M, Sullivan L (1995) Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hyperreflexia. J Urol 154: 1825-1829
95. Giannantoni A, Di Stasi SM, Stephen RL, Navarra P, Scivoletto G, Mearini E, Porena M (2002) Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 167: 1710-1714 (Pubitemid 34240708)
96. Giannantoni A, Di Stasi SM, Nardicchi V, Zucchi A, Macchioni L, Bini V, Goracci G, Porena M (2006a) Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 175: 2341-2344 (Pubitemid 43668538)
97. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M (2006b) Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 49 (4): 704-709 (Pubitemid 43374735)
98. Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E (2008) Botulinum A toxin injection in patients with painful bladder syndrome: 1-year follow-up. J Urol 179: 1031-1034
99. Grossman HB, Liebert M, Lee IW, Lee SW (1994) Decreased connexin expression and intercellular communication in human bladder cancer cells. Cancer Res 54: 3062-3065 (Pubitemid 24187796)
100. Gunthorpe MJ, Chizh BA (2009) Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today 14: 56-67
101. Guo A, Vulchanova L, Wang J, Li X, Elde R (1999) Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 11: 946-958 (Pubitemid 29106055)
102. Haferkampa A, Schurch B, Reitzb A, Krengela U, Grosse J, Kramer G, Schumachera S, Bastiana PJ, Buttnere R, Mullera SC, Stohrer M (2004) Lack of ultrastructural detrusor changes following endoscopic injection of botulinumtoxintype A in overactive neurogenic bladder. Eur Urol 46: 784-791 (Pubitemid 39488414)
103. Hermann H, De Petrocellis L, Bisogno T, Bisogno T, Schiano Moriello A, Lutz B, Di Marzo V (2003) Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptormediated response. Cell Mol Life Sci 60: 607-616 (Pubitemid 36459539)
104. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks JD (2007) Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol 189: 818-832 (Pubitemid 46183856)
105. Holzer P (1991) Capsaicin: cellular target, mechanism of action and selectivity for thin sensory neurons. Pharmacol Rev 43: 143-201
106. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99: 8400-8405 (Pubitemid 34651064)
107. Humeau Y, Doussau F, Grant NJ, Poulain B (2000) How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 82: 427-446 (Pubitemid 30391899)
108. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh YG, Kim D, Oh U (2000) Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 97: 6155-6160 (Pubitemid 30367539)
109. Ibafiez C, Blanes-Mira C, Fernández-Ballester G, Planells-Cases R, Ferrer-Montiel A (2004) Modulation of botulinum neurotoxin A catalytic domain stability by tyrosine phosphorylation. FEBS Lett 578: 121-127 (Pubitemid 39576112)
110. Ichikawa H, Sugimoto T (2001) VR1-immunoreactive primary sensory neurons in the rat trigeminal ganglion. Brain Res 890: 184-188 (Pubitemid 32119538)
111. Igawa Y, Satoh T, Mizusawa H, Seki S, Kato H, Ishizuka O, Nishizawa O (2003) The role of capsaicin-sensitive afferents in autonomic dysreflexia in patients with spinal cord injury. BJU Int 91: 637-641 (Pubitemid 36583734)
112. 2+ influx pathway activated by mechanical stretch in human airway smooth muscle cells. Am J Respir Cell Mol Biol 38: 407-413
113. Jahn R, Scheller RH (2003) SNAREs-engines for membrane fusion. Nat Rev Mol Cell Biol 7: 631-643
114. Jahn R, Lang T, Sudhof TC (2003) Membrane fusion. Cell 112: 519-533 (Pubitemid 36263084)
115. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ (2002) p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia, Neuron 36: 57-68
116. Jones RC, Xu L, Gebhart GF (2005) The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3. J Neurosci 25: 10981-10989 (Pubitemid 41692628)
117. Jordt SE, Julius D (2002) Molecular basis for species-specific sensitivity to "hot" chili peppers, Cell 108: 421-430
118. Jordt SE, Tominaga M, Julius D (2000) Acid potentiation of the capsaicin receptor determined by a key extracellular site. Proc Natl Acad Sci USA 97: 8134-8139 (Pubitemid 30460785)
119. 2+/calmodulin-dependent kinase II regulates its vanilloid binding. J Biol Chem 279: 7048-7054
120. Kadowaki M, Kuramoto H, Takaki M (2004) Combined determination with functional and morphological studies of origin of nerve fibers expressing transient receptor potential vanilloid 1 in the myenteric plexus of rat jejunum, Auton Neurosci 116: 11-18 (Pubitemid 39535369)
121. Kalandakanond S, Coffield JA (2001) Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J Pharmacol Exp Ther 296: 980-986 (Pubitemid 32187373)
122. Kalsi V, Gonzales G, Popat R, Apostolidis A, Elneil S, Dasgupta P, Fowler CJ (2007) Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 62 (5): 452-457 (Pubitemid 350308769)
123. Kark T, Bagi Z, Lizanecz E, Pásztor ET, Erdei N, Czikora A, Papp Z, Edes I, Pórszász R, Tóth A (2008) Tissue-specific regulation of microvascular diameter: opposite functional roles of neuronal and smooth muscle located vanilloid receptor-1. Mol Pharmacol 73: 1405-1412 (Pubitemid 351574830)
124. Khairatkar-Joshi N, Szallasi A (2009) TRPV1 antagonists: the challenges for therapeutic targeting. Trends Mol Med 15: 14-22
125. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP (2004) Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 45: 987-993 (Pubitemid 39164923)
126. Kim JH, Rivas DA, Shenot PJ, Green B, Kennelly M, Erickson JR, O'Leary M, Yoshimura N, Chancellor MB (2003) Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med 26: 358-363 (Pubitemid 37549376)
127. Kim JC, Park EY, Hong SH, Seo SI, Park YH, Hwang TK (2005) Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol 12: 875-878
128. Koike S, Uno T, Bamba H, Shibata T, Okano H, Hisa Y (2004) Distribution of vanilloid receptors in the rat laryngeal innervation. Acta Otolaryngol 124: 515-519 (Pubitemid 38797617)
129. Koplas PA, Rosenberg RL, Oxford GS (1997) The role of calcium in the desensitization of capsaicin responses in rat dorsal root ganglion neurons, J Neurosci 17: 3525-3537 (Pubitemid 27200581)
130. Koriazova LK, Montai M (2003) Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10: 13-18 (Pubitemid 36034171)
131. Kuenzi FM, Dale N (1996) Effect of capsaicin and analogues on potassium and calcium currents and vanilloid receptors in Xenopus embryo spinal neurones. Br J Pharmacol 119: 81-90 (Pubitemid 26294526)
132. Kuo HC (2003) Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J Urol 170: 835-839
133. Kuo HC (2005a) Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics. BJU Int 95: 1023-1027
134. Kuo HC (2005b) Prostate botulinum A toxin injection: an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65: 670-674
135. Kuo HC, Liu HT, Yang WC (2006) Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. J Urol 176: 641-645
136. Kuo HC, Liu HT, Chancellor MB (2009) Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn 29: 482-487
137. Lacy BD, Stevens RC (1999) Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 291: 1091-1104
138. Lakshmi S, Joshi PG (2005) Co-activation of P2Y2 receptor and TRPV channel by ATP: implications for ATP induced pain. Cell Mol Neurobiol 25: 819-832 (Pubitemid 41160101)
139. Lalli G, Herreros J, Osborne SL, Montecucco C, Rossetto O, Schiavo G (1999) Functional characterisation of tetanus and botulinum neurotoxins binding domains. J Cell Sci 112: 2715-2724 (Pubitemid 29429794)
140. Lazzeri M, Beneforti P, Benaim G, Maggi CA, Lecci A, Turini D (1996) Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. J Urol 156: 947-952 (Pubitemid 26269807)
141. Lazzeri M, Beneforti P, Turini D (1997) Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J Urol 158: 2093-2096 (Pubitemid 27481334)
142. Lazzeri M, Spinelli M, Beneforti P, Zanollo A, Turini D (1998) Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases. Scand J Urol. Nephrol 32: 331-334 (Pubitemid 28494068)
143. Lazzeri M, Beneforti M, Spinelli A, Zanollo A, Barbagli G, Turini D (2000) Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol 164: 676-679 (Pubitemid 30637600)
144. Lazzeri M, Vannucchi MG, Zardo C, Spinelli M, Beneforti P, Turini D,
145. Lazzeri M, Spinelli M, Zanollo A, Turini D (2004b) Intravesical vanilloids and neurogenic incontinence: ten years experience. Urol Int 72: 145-149 (Pubitemid 38223800)
146. Lee SY, Lee JH, Kang KK, Hwang SY, Choi KD, Oh U (2005) Sensitization of vanilloid receptor involves an increase in the phosphorylated form of the channel. Arch Pharm Res 28: 405-412
147. Li L, Binz T, Niemann H, Singh BR (2000) Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain. Biochemistry 39: 2399-2405 (Pubitemid 30130092)
148. Lishko PV, Procko E, Jin X, Phels CB, Gaudet R (2007) The ankyrin repeats of TRPV1 bind multiple ligands and modulate channel sensitivity. Neuron 54: 905-918 (Pubitemid 46907502)
149. Liu HT, Kuo HC (2007a) Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 70: 463-468
150. Liu HT, Kuo HC (2007b) Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity. BJU Int 100: 1086-1090
151. Liu B, Zhang C, Qin F (2005) Functional recovery from desensitization of vanilloid receptor TRPV1 requires resynthesis of phosphatidylinositol 4,5-biphosphate. J Neurosci 25: 4835-4843 (Pubitemid 40664131)
152. Liu HT, Chancellor MB, Kuo HC (2008) Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 56 (4): 700-707
153. Liu HT, Chancellor MB, Kuo HC (2009) Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 56: 700-706
154. 2+)-dependent transport of acetylcholine in reconstituted giant liposomes made from presynaptic membranes from cholinergic nerve terminals. Neurosci Lett 196: 37-40
155. Lu G, Henderson D, Liu L, Reinhart PH, Simon SA (2005) TRPV1b, a functional human vanilloid receptor splice variant. Mol Pharmacol 67: 1119-1127 (Pubitemid 40410412)
156. Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE (2008) Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 101: 366-370
157. Mahmmoud YA (2008) Capsazepine, a synthetic vanilloid that converts the Na, K-ATPase to Na-ATPase. Proc Natl. Acad Sci USA 105: 1757-1761
158. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 580: 2011-2014
159. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62: 259-264 (Pubitemid 36952073)
160. Marsal J, Egea G, Solsona C, Rabasseda X, Blasi J (1989) Botulinum toxin type A blocks the morphological changes induced by chemical stimulation on the presynaptic membrane of Torpedo synaptosomes Proc Natl Acad Sci USA 86: 372-376
161. McCroskey LM, Hatheway CL, Woodruff BA, Greenberg JA, Jurgenson P (1991) Type F botulism due to neurotoxigenic Clostridium baratii from an unknown source in an adult. J Clin Microbiol 29 (11): 2618-2620
162. McIntyre P, McLatchie LM, Chambers A, Phillips E, Clarke M, Savidge J, Toms C, Peacock M, Shah K, Winter J, Weerasakera N, Webb M, Rang HP, Bevan S, James IF (2001) Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br J Pharmacol 132: 1084-1094 (Pubitemid 32238914)
163. McNew JA, Parlati F, Fukuda R, Johnston RJ, Paz K, Paumet F, Söllner TH, Rothman JE (2000) Compartmental specificity of cellular membrane fusion encoded in SNARE proteins. Nature 407 (6801): 153-159
164. McVary KT, McKenna KE, Lee C (1998) Prostate innervation. Prostate Suppl 8: 2-13 (Pubitemid 28347989)
165. McVey DC, Vigna SR (2001) The capsaicin VR1 receptor mediates substance P release in toxin Ainduced enteritis in rats. Peptides 22: 1439-1446 (Pubitemid 32770015)
166. Meng X, Karasawa T, Zou K, Kuang X, Wang X, Lu C, Wang C, Yamakawa K, Nakamura S (1997) Characterization of a neurotoxigenic Clostridium butyricum strain isolated from the food implicated in an outbreak of food-borne type E botulism. J Clin Microbiol 35 (8): 2160-2162
167. Meunier FA, Schiavo G, Molgó J (2002) Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 96: 105-113 (Pubitemid 34087038)
168. Mezey E, Tóth ZE, Cortright DN, Arzubi MK, Krause JE, Eide R, Guo A, Blumberg PM, Szallasi A (2000) Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 97: 3655-3660 (Pubitemid 30183358)
169. Michael GJ, Priestley JV (1999) Differential expression of the mRNA for the vanilloid receptor subtype 1 in cells of the adult rat dorsal root and nodose ganglia and its downregulation by axotomy. J Neurosci 19: 1844-1854 (Pubitemid 29094200)
170. Mizumura K, Sugiur T, Koda H, Katanosaka K, Kumar BR, Giron R, Tominaga M (2005) Pain and bradykinin receptors - sensory transduction mechanism in the nociceptor terminals and expression change of bradykinin receptors in inflamed condition, Nihon Shinkei Seishin Yakurigaku Zasshi 25: 33-38 (Pubitemid 40403949)
171. Mohanty S, Dhawan B, Chaudhry R (2001) Botulism: an update. Indian J Med Microbiol 19: 35-43
172. 2+-dependent desensitization in the vanilloids receptor TRPV1 by calcineurin and cAMP-dependent protein kinase, J Biol Chem 280: 13424-13432
173. Montal M (2009) Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel. Toxicon 54: 565-569
174. Morenilla-Palao C., Planells-Cases R, García-Sanz N, Ferrer-Montiel A (2004) Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 279: 25665-25672 (Pubitemid 38756829)
175. Moriyama T, lida T, Kobayashi K, Higashi T, Fukuoka T, Tsumura H, Leon C, Suzuki N, Inoue K, Gachet C, Noguchi K, Tominaga M (2003) Possible involvement of P2Y2 metabotropic receptors in ATP-induced transient receptor potential vanilloid receptor 1-mediated thermal hypersensitivity. J Neurosci 23: 6058-6062
176. Mukerji G, Yiangou Y, Agarwal SK, Anand P (2006) Transient receptor potential vanilloid receptor subtype 1 in painful bladder syndrome and its correlation with pain. J Urol 176: 797-801 (Pubitemid 43927917)
177. Muller D, Garcia-Segura LM, Parducz A, Dunant Y (1987) Brief occurrence of a population of presynaptic intramembrane particles coincides with transmission of a nerve impulse. Proc Natl Acad Sci USA 84: 590-594 (Pubitemid 17006241)
178. Novakova-Tousova K, Vyklicky L, Susankova K, Benedikt J, Samad A, Teisinger J, Vlachova V (2007) Functional changes in the vanilloids receptor subtype 1 channel during and after acute desensitization. Neuroscience 149: 144-154 (Pubitemid 47496200)
179. Oh GS, Pae HO, Seo WG, Kim NY, Pyun KH, Kim IK, Shin M, Chung HT (2001) Capsazepine, a vanilloid receptor antagonist, inhibits the expression of inducible nitric oxide synthase gene in lipopolysaccharide-stimulated RAW264.7 macrophages through the inactivation of nuclear transcription factor-kappa B. Int Immunopharmacol 1: 777-784 (Pubitemid 32206539)
180. Ohta T, Ikemi Y, Murakami M, Imagawa T, Otsuguro K, Ito S (2006) Potentiation of transient receptor potential V1 functions by the activation of metabotropic 5-HT receptors in rat primary sensory neurons. J Physiol 576: 809-822 (Pubitemid 44637885)
181. Ost D, Roskams T, Van Der Aa F, De Ridder D (2002) Topography of the vanilloid receptor in the human bladder: more than just the nerve fibers. J Urol 168: 293-297 (Pubitemid 34640847)
182. Payne CK, Mosbaugh PG, Forrest JB, Evans RJ, Whitmore KE, Antoci JP, Perez-Marrero R, Jacoby K, Diokno AC, O'Reilly KJ, Griebling TL, Vasavada SP, Yu AS, Frumkin LR (2005) Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol 173: 1590-1594 (Pubitemid 40524779)
183. Peng CH, Kuo HC (2007) Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis, Urol Int 78: 78-81
184. Perkins MN, Campbell EA (1992) Capsazepine reversal of the antinociceptive action of capsaicin in vivo. Br J Pharmacol 107: 329-333
185. Pinto R, Silva A, Lopes T, Silva J, Silva C, Cruz F, Dinis P (2009) Intra-trigonal injection of botulinum toxin A in patients with bladder pain syndrome. Results at 9-months of follow-up, J Urol 181:20
186. Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, Cruz C, Cruz F, Dinis P (2010) Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 58: 360-365
187. Piper AS, Yeats JC, Bevan S, Docherty RJ (1999) A study of the voltage dependence of capsaicinactivated membrane currents in rat sensory neurones before and after acute desensitization. J Physiol 518: 721-733 (Pubitemid 29387242)
188. Popoff M, Marvaud JC (1999) Structural and genomic features of clostridial neurotoxins, In: Alouf JE, Freer JH (eds) The comprehensive sourcebook of bacterial protein toxins. Academic, London, pp 202-228
189. Premkumar LS, Ahern GP (2000) Induction of vanilloid receptor channel activity by protein kinase C. Nature 408: 985-990 (Pubitemid 32101646)
190. Prescott ED, Julius D (2003) A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science 300: 1284-1288 (Pubitemid 36618238)
191. Prescott GR, Gorleku OA, Greaves J, Chamberlain LH (2009) Palmitoylation of the synaptic vesicle fusion machinery. J Neurochem 110: 1135-1149
192. Purkiss J, Welch M, Doward S, Foster K (2000) Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 59: 1403-1406 (Pubitemid 30177357)
193. Rapp DE, Turk KW, Bales GT, Cook SP (2006) Botulinum toxin type A inhibits calcitonin generelated peptide release from isolated rat bladder. J Urol 175: 1138-1142 (Pubitemid 43200117)
194. Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45: 510-515 (Pubitemid 38376219)
195. Rigoni M, Caccin P, Johnson EA, Montecucco C, Rossetto O (2001) Site-directed mutagenesis identifies active-site residues of the light chain of botulinum neurotoxin type A. Biochem Biophys Res Commun 288: 1231-1237 (Pubitemid 33131733)
196. Rohacs T, Thyagarajan B1 Lukacs V (2008) Phospholipase C mediated modulation of TRPV1 channels. Mol Neurobiol 37: 153-163
197. Rummel A, Mahrhold S, Bigalke H, Binz T (2004) The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 51: 631-643 (Pubitemid 38233933)
198. Sahai A, Khan MS, Dasgupta P (2007) Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebocontrolled trial, J Urol 177: 2231-2236 (Pubitemid 46726400)
199. Sakaba T, Stein A, Jahn R, Neher E (2005) Distinct kinetic changes in neurotransmitter release after SNARE protein cleavage. Science 309: 491-494 (Pubitemid 40994692)
200. Santos-Buelga JA, Collins MD, East AK (1998) Characterization of the genes encoding the botulinum neurotoxin complex in a strain of Clostridium botulinum producing type B and F neurotoxins, Curr Microbiol 37: 312-318
201. Schaible HG, Del Rosso A, Matucci-Cerinic M (2005) Neurogenic aspects of inflammation. Rheum Dis Clin North Am 31: 77-101 (Pubitemid 40082056)
202. Schiavo G, Rossetto O, Benfenati F, Poulain B, Montecucco C (1994) Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann NY Acad Sci 710: 65-75 (Pubitemid 24119183)
203. Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176: 177-185 (Pubitemid 43815416)
204. Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Stürzebecher B1 Miller K, Knispel HH (2005) Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction, Eur Urol 48: 984-990 (Pubitemid 41641650)
205. Schulte-Baukloh H, Zurawski TH, Knispel HH, Miller K, Haferkamp A, Dolly JO (2007) Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. BJU Int 100: 1075-1080 (Pubitemid 47537663)
206. Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, PerrouinVerbe B, Kumar C, Fraczek S, Brin MF, Botox Detrusor Hyperreflexia Study Team (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 (1): 196-200
207. Shin J, Cho H, Hwang SW, Jung J, Shin CY, Lee SY, Kim SH, Lee MG, Choi YH, Kim J, Haber NA, Reichling DB, Khasar S, Levine JD, Oh U (2002) Bradykinin-12-1 ipoxygenaseVR1 signaling pathway for inflammatory hyperalgesia. Proc Natl Acad Sci USA 99: 10150-10155 (Pubitemid 34831187)
208. Silva C, Rio ME, Cruz F (2000) Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia. Eur Urol 38: 444-452
209. Silva C, Ribeiro MJ, Cruz F (2002) The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 168: 575-579 (Pubitemid 34793300)
210. Silva C, Silva J, Ribeiro MJ, Avelino A, Cruz F (2005) Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. Eur Urol 48: 650-655 (Pubitemid 41278592)
211. Silva C, Silva J, Castro H, Reis F, Dinis P, Avelino A, Cruz F (2007) Bladder sensory desensitization decreases urinary urgency. BMC Urol 11: 7-9
212. Silva A, Cruz CD, Charrua A, Pinto R, Avelino A, Silva C, Dinis P, Cruz F (2008a) GRC 6211, a new oral TRPV1 antagonist, decreases neurogenic detrusor overactivity in a rat model of spinal cord transection. Neurourol Urodyn 27 (7): 597-598
213. Silva J, Pinto R, Carvallho T, Coelho A, Avelino A, Dinis P, Cruz F (2008b) Mechanisms of prostate atrophy after glandular botulinum neurotoxin type A injection: an experimental study in the rat. Eur Urol 56: 134-141
214. Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, Cruz F (2008c) Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement, Effect on prostate volume and micturition resumption. Eur Urol 53: 153-159 (Pubitemid 350166733)
215. Simpson LL (1981) The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 33: 155-188
216. Simpson LL (1984) Botulinum toxin and tetanus toxin recognize similar membrane determinants, Brain Res 305 (1): 177-180
217. Simpson LL, Maksymowych AB, Hao S (2001) The role of zinc binding in the biological activity of botulinum toxin. J Biol Chem 276: 27034-27041
218. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB (2004) Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 64: 871-875 (Pubitemid 39469494)
219. Smith CP, Gangitano DA, Munoz A, Salas NA, Boone TB, Aoki KR, Francis J, Somogyi GT (2008) Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int 52: 1068-1075
220. Southall MD, Li T, Gharibova LS, Pei Y, Nicol GD, Travers JB (2003) Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes, J Pharmacol Exp Ther 304: 217-222 (Pubitemid 36008931)
221. Ständer S, Moormann C, Schumacher M, Buddenkotte J, Artuc M, Shpacovitch V, Brzoska T, Lippert U, Henz BM, Luger TA, Metze D, Steinhoff M (2004) Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol 13: 129-139 (Pubitemid 38380276)
222. Stein EA, Fuller SA, Edgemond WS, Campbell WB (1996) Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br J Pharmacol 119: 107-114 (Pubitemid 26294529)
223. Stein AT, Ufret-Vincenty CA, Hua L, Santana LF, Gordon SE (2006) Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane. J Gen Physiol 128: 509-522 (Pubitemid 44664629)
224. Steiner AA, Turek VF, Almeida MC, Burmeister JJ, Oliveira DL, Roberts JL, Bannon AW, Norman MH, Louis JC, Treanor JJS, Gavva NR, Romanovsky AA (2007) Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J Neurosci 27: 7459-7468 (Pubitemid 47066573)
225. Strauss HM, Keller S (2008) Pharmacological interference with protein-protein interactions mediated by coiled-coil motifs. Handb Exp Pharmacol 186: 461-482
226. Südhof TC, Rothman JE (2009) Membrane fusion: grappling with SNARE and SM proteins. Science 323: 474-477
227. Sugiura T, Tominaga M, Katsuya H, Mizumura K (2002) Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. J Neurophysiol 88: 544-548 (Pubitemid 34755376)
228. Swanson DM, Dubin AE, Shah C, Nasser N, Chang L, Dax SL, Jetter M, Breitenbucher JG, Liu C, Mazur C, Lord B, Gonzales L, Hoey K, Rizzolio M, Bogenstaetter M, Codd EE, Lee DH, Zhang SP, Chaplan SR, Carruthers NI (2005) Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl) piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl) amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J Med Chem 48: 1857-1872 (Pubitemid 40396317)
229. 3H]Resiniferatoxin binding to central (spinal cord and dorsal root ganglia) and peripheral (urinary bladder and airways) vanilloid (capsaicin) receptors in the rat. J Pharmcol Exp Ther 267: 728-733
230. Szallasi A, Cruz F, Geppetti P (2006) TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol. Med 12 (11): 545-554 (Pubitemid 44633805)
231. Szallasi A, Cortright DN, Blum CA, Eid SR (2007) The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of concept, Nat Rev Drug Discov 6: 357-372 (Pubitemid 46705200)
232. Tang HB, Inoue A, Oshita K, Nakata Y (2004) Sensitization of vanilloid receptor 1 induced by bradykinin via the activation of second messenger signaling cascades in rat primary afferent neurons. Eur J Pharmacol 498: 37-43 (Pubitemid 39208058)
233. Thesleff S, Molgó J, Tågerud S (1990) Trophic interrelations at the neuromuscular junction as revealed by the use of botulinal neurotoxins. J Physiol Paris 84: 167-173 (Pubitemid 20327512)
234. Tohda C, Sasaki M, Konemura T, Sasamura T, Itoh M, Kuraishi Y (2001) Axonal transport of VR1 capsaicin receptor mRNA in primary afférents and its participation in inflammation-induced increase in capsaicin sensitivity, J Neurochem 76: 1628-1635 (Pubitemid 32221102)
235. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli, Neuron 21: 531-543 (Pubitemid 28475505)
236. Tominaga M, Wada M, Masu M (2001) Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci USA 98: 6951-6956 (Pubitemid 32538323)
237. Tominaga M, Numazaki M, lida T, Tominaga T (2003) Molecular mechanisms of nociception, Nihon Shinkei Seishin Yakurigaku Zasshi 23: 139-147
238. Tótn A, Boczán J, Kedei N, Lizanecz E, Bagi Z, Papp Z, Edes I, Csiba L, Blumberg PM (2005) Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res 135: 162-168 (Pubitemid 40602409)
239. Turner H, Fleig A, Stokes A, Kinet JP, Penner R (2003) Discrimination of intracellular calcium store subcompartments using TRPV1 (transient receptor potential channel, vanilloid subfamily member 1) release channel activity. Biochem J 371: 341-350 (Pubitemid 36547616)
240. Tyagi V, Philips BJ, Su R, Smaldone MC, Erickson VL, Chancellor MB, Yoshimura N, Tyagi P (2009) Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 181 (4): 1932-1938
241. Urban L, Dray A (1991) Capsazepine, a novel capsaicin antagonist, selectively antagonises the effects of capsaicin in the mouse spinal cord in vitro. Neurosci Lett 134: 9-11
242. Van Buren JJ, Bhat S, Rotello R, Pauza ME, Premkumar LS (2005) Sensitization and translocation of TRPV1 by insulin and IGF-I. Mol Pain 1: 17-28
243. Vassilieva EV, Nusrat A (2008) Vesicular trafficking: molecular tools and targets. Methods Mol Biol 440: 3-14
244. Vellani V, Mapplebeck S, Moriondo A, Davis JB, McNaughton PA (2001) Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol 534: 813-825 (Pubitemid 32700878)
245. Veronesi B, Oortgiesen M, Roy J, Carter JD, Simon SA, Gavett SH (2000) Vanilloid (capsaicin) receptors influence inflammatory sensitivity in response to particulate matter. Toxicol Appl Pharmacol 169: 66-76
246. Vetter I, Wyse BD, Monteith GR, Roberts-Thomson SJ, Cabot PJ (2006) The mu opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway. Mol Pain 2: 22-37
247. Vetter I, Cheng W, Peiris M, Wyse BD, Roberts-Thomson SJ, Zheng J, Monteith GR, Cabot PJ (2008) Rapid, opioid-sensitive mechanisms involved in transient receptor potential vanilloid 1 sensitization. J Biol Chem 283: 19540-19550
248. Vlaskovska M, Kasakov L, Rong W, Bodin P, Bardini M, Cockayne DA, Ford AP, Burnstock G (2001) P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci 21: 5670-5677 (Pubitemid 32692165)
249. Voets T, Nilius B (2007) Modulation of TRPs by PIPs. J Physiol 582: 939-944 (Pubitemid 47104330)
250. Voilley N, de Weille J, Mamet J, Lazdunski M (2001) Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J Neurosci 21: 8026-8033 (Pubitemid 32952759)
251. Vos MH, Neelands TR, McDonald HA, Choi W, Kroeger PE, Puttfarcken PS, Faltynek CR, Moreland RB, Han P (2006) TRPVIb overexpression negatively regulates TRPV1 responsiveness to capsaicin, heat and low pH in HEK293 cells. J Neurochem 99: 1088-1102 (Pubitemid 44655275)
252. Vyklický L, Nováková-Tousová K, Benedikt J, Samad A, Touska F, Vlachová V (2008) Calciumdependent desensitization of vanilloid receptor TRPV1: a mechanism possibly involved in analgesia induced by topical application of capsaicin. Physiol Res 57: S59-S68
253. Wagman J (1954) Isolation and sedimentation study of low molecular weight forms of type A botulinus toxin. Arch Biochem Biophys 50: 104-112
254. Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ, McIntyre P (2003) The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 304: 56-62 (Pubitemid 36008912)
255. Walpole CS, Bevan S, Bovermann G, Boelsterli JJ, Breckenridge R, Davies JW, Hughes GA, James I, Oberer L, Winter J, Wrigglesworth R (1994) The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J Med Chem 37: 1942-1954 (Pubitemid 24233606)
256. Wang C, Hu HZ, Colton CK, Wood JD, Zhu MX (2004) An alternative splicing product of the murine trpv1 gene dominant negatively modulates the activity of TRPV1 channels. J Biol Chem 279: 37423-37430 (Pubitemid 39195451)
257. Wang EC, Lee JM, Ruiz WG, Balestreire EM, von Bodungen M, Barriek S, Cockayne DA, Birder LA, Apodaca G (2005) ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. J Clin Invest 115: 2412-2422 (Pubitemid 41266203)
258. Wang YX, Wang J, Wang C, Liu J, Shi LP, Xu M, Wang C (2008a) Functional expression of transient receptor potential vanilloid-related channels in chronically hypoxic human pulmonary arterial smooth muscle cells. J Membr Biol 223: 151-159
259. Wang ZY, Wang P, Merriam FV, Bjorling DE (2008b) Lack of TRPV1 inhibits cystitis-induced increased mechanical sensitivity in mice. Pain 139: 158-167
260. Welch JM, Simon SA, Reinhart PH (2000a) The activation mechanism of rat vanilloid receptor 1 by capsaicin involves the pore domain and differs from the activation by either acid or heat. Proc Natl Acad Sci USA 97: 13889-13894
261. Welch MJ, Purkiss JR, Foster KA (2000b) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38: 245-258
262. Wiart L, Joseph PA, Petit H, Dosque JP, de Sèze M, Brochet B, Deminière C, Ferrière JM, Mazaux JM, N'Guyen P, Barat M (1998) The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease, Preliminary results. Spinal Cord 36: 95-99
263. Wickner W, Schekman R (2008) Membrane fusion. Nat Struct Mol Biol 15: 658-664 (Pubitemid 351932008)
264. Wong GY, Gavva NR (2008) Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks, Brain Res Rev 60: 267-277
265. 2+ uptake by synaptosomes and its effect on the inhibition of acetylcholine release by botulinum toxin. J Neurochem 30: 1127-1134
266. Yang X, Han JQ, Liu R (2008) Effects of experimental colitis on the expressions of calcitonin gene-related peptide and vanilloid receptor 1 in rat spinal cord sensory neurons, Acta Physiol Sinica 60: 143-148
267. Yokoyama T, Kumon H, Nagai A (2008) Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodyn 27: 417-420 (Pubitemid 351991207)
268. Yowler BC, Schengrund CL (2004) Glycosphingolipids: sweets for botulinum neurotoxin, Glycoconj J 21: 287-293
269. Zhu W, Oxford GS (2007) Phosphoinositide-3-kinase and mitogen activated protein kinase signaling pathways mediate acute NGF sensitization of TRPV1. Mol Cell Neurosci 34: 689-700 (Pubitemid 46486710)
270. Zhuang ZY, Xu H, Clapham DE, Ji RR (2004) Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization, J Neurosci 24: 8300-8309 (Pubitemid 39280809)
271. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Högestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457 (Pubitemid 29361798)